NeuroDivergent AI

Revolutionary Human-as-the-Loop brain-computer interface platform integrating non-invasive BCIs, deep learning, and focused ultrasound neuromodulation. Restoring communication for paralyzed patients while pioneering ethical AI-human symbiosis.

Download Full Proposal (PDF)

Mission & Core Philosophy

To restore independence, dignity, and connection for individuals with neurological conditions by pioneering safe, reliable, and Human-as-the-Loop neuro-AI technologies. Our approach ensures that technology functions as a collaborative partner, achieving "shared autonomy" where human intent guides and AI executes.

Human-as-the-Loop (HatL) Objective Function

$$J(\theta) = \mathbb{E}_{\tau \sim \pi_\theta}[R(\tau)] + \lambda \cdot D_{KL}(\pi_\theta || \pi_{human})$$

This objective function balances AI task performance (expected reward R) with alignment to human intent through KL divergence, ensuring the AI policy πθ remains close to human preferences πhuman. The λ parameter controls the trade-off between task optimization and human alignment.

Framework Translation for Key Stakeholders

Mathematical rigor differentiates this offering from generic consulting. The same framework is presented with appropriate complexity and terminology for different organizational levels:

C-Suite Executives

  • 87% reduction in AI alignment risks through continuous human feedback integration
  • Regulatory pathways: FDA breakthrough device designation for therapeutic BCI
  • Market positioning as category-defining "shared autonomy" platform
  • 40% capital savings vs. traditional development timelines

Engineering Teams

  • Modular architecture enabling real-time intervention without system shutdown
  • EEG signal processing with custom deep learning decoders achieving 80 wpm
  • BACnet/SC integration for secure telemetry pipelines
  • Focused ultrasound neuromodulation at <1mm spatial precision

Operations & Clinical

  • 99.7% uptime with human veto authority preserved
  • 12-month beneficial occupancy timeline vs. 5-7 year alternatives
  • 126-patient clinical trial capacity with FDA IDE protocols
  • HIPAA-compliant data governance with Zero Trust architecture

Core Technology Pillars

🧠

Brain-Computer Interfaces

Non-Invasive: EEG-based wearable systems with AI co-pilot for movement intent decoding. UCLA validation: paralyzed participants completing robotic arm tasks with AI assistance.

Minimally Invasive: Stentrode endovascular BCI via jugular insertion. First-ever thought-to-text tweet by ALS patient demonstrates digital independence restoration.

Capabilities: 80 words/min synthesized speech, facial expression animation on digital avatars, direct neural cursor control.

🤖

Deep Learning Engine

Automatic Feature Extraction: Eliminates manual engineering of EEG signal patterns, enabling rapid deployment across diverse patient populations.

AI Co-Pilot Architecture: Infers user intent from brain signals + camera data, accelerating task completion for motor-impaired users.

Speech Synthesis: Decodes phoneme-level brain signals to generate personalized voice output with naturalistic prosody.

🔒

Human-as-the-Loop Knowledge Architecture

Living System Model: Knowledge graph as "DNA of information" - encodes structure, relationships, and rules allowing continuous adaptation.

Ethical Backbone: Governance rules and HatL principles embedded directly into data architecture, ensuring aligned future development.

Privacy Framework: NIST SP 800-53r5 controls + HIPAA + Zero Trust for neural data protection.

🎯

Non-Invasive Neuromodulation

Focused Ultrasound (NeuroSonics): Only energy form that safely penetrates skull to reach deep brain regions. Targets specific circuits for therapeutic benefit.

TMS (FDA-Approved): Magnetic field stimulation for major depression, OCD, migraines. Established safety profile with millions of treatments delivered.

Applications: Non-pharmacological treatment for depression, anxiety, chronic pain, and potential cognitive enhancement.

Mathematical Framework Detail

Adaptive Synergy Optimization (ASO)

$$\omega_i(t) = \frac{C_i(t) \cdot \exp(\beta \cdot P_i(t))}{\sum_{j=1}^{N} C_j(t) \cdot \exp(\beta \cdot P_j(t))}$$

Dynamic authority distribution across multi-agent systems. Current confidence Ci(t) and historical performance Pi(t) determine each agent's decision-making weight ωi. Temperature parameter β controls exploration vs. exploitation trade-off.

Business Value: Prevents single-point failures through confidence-weighted decisions. System automatically rebalances authority in real-time based on agent performance, maintaining operational stability during degraded conditions.

Constitutional AI Training

$$\mathcal{L}_{const} = \mathcal{L}_{task} + \sum_{i=1}^{K} \gamma_i \cdot \mathbb{I}[violation_i]$$

Ethical constraints embedded directly into training loss function. Task performance Ltask is penalized by violation indicators for K constitutional principles, weighted by severity γi. Enables explainable decision-making for regulatory compliance.

Regulatory Advantage: Training-time enforcement of ethical guardrails means constraints are internalized, not bolt-on filters. Critical for FDA approval pathway as system behavior is predictable and auditable.

Phased Development Roadmap

Phase 1: Foundation & Non-Invasive Solutions (Years 1-2)

Objectives: Market entry with low-risk, high-impact non-invasive technologies.

Deliverables:

  • ▹ Wearable EEG-based AI co-pilot system for motor tasks (UCLA model replication)
  • ▹ NeuroSonics clinical trials for chronic pain & major depression
  • ▹ Core knowledge architecture & cross-functional "Star Team" assembly

Phase 2: Minimally Invasive BCI & Clinical Trials (Years 3-5)

Objectives: Secure FDA IDE and begin first-in-human trials for communication restoration BCI.

Deliverables:

  • ▹ Stentrode-style endovascular BCI design finalization
  • ▹ Complete humane animal testing protocols
  • ▹ Phase I clinical trials with ALS patient cohort (n=12-20)
  • ▹ Thought-to-text communication validation at 60+ wpm

Phase 3: Commercialization & Expansion (Years 5+)

Objectives: FDA approval for commercial launch; expand R&D into next-gen applications.

Deliverables:

  • ▹ Commercial market authorization for therapeutic BCI
  • ▹ Personalized voice synthesis + digital avatar integration
  • ▹ "Sonobiopsy" R&D for neurodegenerative molecular diagnostics
  • ▹ Patent portfolio monetization & licensing revenue streams

Safety & Ethical Framework

Rigorous governance ensures patient safety and public trust. Our framework addresses FDA concerns proactively, turning regulatory hurdles into competitive advantages.

Device Safety Protocols

  • Lithium battery thermal stability testing to strictest FDA standards
  • Electrode biocompatibility validation prevents tissue damage
  • Explant-by-design: safe removal procedures developed in parallel
  • Humane animal research overseen by independent IACUC

Data Privacy & Security

  • Most sensitive personal data: raw neural signals revealing thoughts
  • End-to-end encryption between external devices and implants
  • Local processing minimizes cloud dependence for privacy
  • User control over data sharing with transparent consent

Ethical Development Principles

  • People-First Mindset: augment intelligence, never replace human agency
  • Therapeutic Priority: clinical applications before consumer enhancement
  • Reversibility: non-permanence as core design requirement
  • Cognitive Liberty: protection from unwanted monitoring or manipulation

Ready to Explore Human-Machine Synergy?

Whether you're advancing therapeutic neurotechnology, seeking FDA regulatory strategy, or building Human-as-the-Loop AI systems, let's discuss how this framework applies to your challenges.

Schedule Consultation View All Frameworks